Home Cart Sign in  
Chemical Structure| 550-99-2 Chemical Structure| 550-99-2

Structure of Naphazoline HCl
CAS No.: 550-99-2

Chemical Structure| 550-99-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Naphazoline HCl is a direct-acting sympathomimetic amine with vasoconstrictive activity.

Synonyms: Naphthazoline hydrochloride; Naphazoline (hydrochloride); Vasocon

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Naphazoline HCl

CAS No. :550-99-2
Formula : C14H15ClN2
M.W : 246.74
SMILES Code : C1(CC2=NCCN2)=CC=CC3=CC=CC=C13.Cl
Synonyms :
Naphthazoline hydrochloride; Naphazoline (hydrochloride); Vasocon
MDL No. :MFCD00012554

Safety of Naphazoline HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Naphazoline HCl

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03490682 Pregnancy Hea... More >>lthy Volunteers Parturition Less << Not Applicable Recruiting May 17, 2020 France ... More >> Hospices Civils de Lyon Recruiting Bron, France, 69500 Contact: Lionel BOUVET, MD    4 72 12 97 63 ext +33    lionel.bouvet@chu-lyon.fr    Principal Investigator: Lionel BOUVET, MD Less <<
NCT00536367 - Completed - United States, Ohio ... More >> The Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT03324113 Neoplasm Malignant Phase 1 Active, not recruiting January 2019 Japan ... More >> Investigational Site Number 3920003 Kashiwa-Shi, Japan Investigational Site Number 3920002 Nagoya-Shi, Japan Investigational Site Number 3920001 Sunto-Gun, Japan Less <<
NCT03077308 - Recruiting July 31, 2019 United States, Colorado ... More >> University of Colorado Denver Recruiting Denver, Colorado, United States, 80045-2571 Contact: Gina VanderVeen    720-777-5514    Gina.VanderVeen@childrenscolorado.org    Principal Investigator: Tim Benke, MD, PhD          United States, Massachusetts Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115-5724 Contact: Mustafa Sahin, MD, PhD    617-355-8994    mustafa.sahin@childrens.harvard.edu    Contact: Lindsay Swanson    617-355-8994    lindsay.swanson@childrens.harvard.edu    United States, New York University of Rochester Recruiting Rochester, New York, United States, 14627-0140 Contact: To be named          Principal Investigator: Alex Paciorkowski, MD, PhD          Sub-Investigator: Laurie Seltzer, MD          United States, Ohio Cincinnati Children's Hospital Recruiting Cincinnati, Ohio, United States, 45229 Contact: Max Mays    513-803-7935    Maxwell.Mays@cchmc.org    Principal Investigator: Shannon Standridge, DO          United States, Pennsylvania Children's Hospital of Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19104-4318 Contact: Casey Gorman    267-426-5171    GormanC@email.chop.edu    Principal Investigator: Eric Marsh, MD, PhD          United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37212 Contact: Nicole Thompson    615-343-4586    Nicole.i.thompson@vanderbilt.edu    Principal Investigator: Sar Peters, PhD          Sub-Investigator: Cary Fu, MD Less <<
NCT02601235 Nasal Congestion Phase 3 Recruiting September 2018 Brazil ... More >> Faculdade de Medicina do ABC Recruiting Santo André, SP, Brazil Principal Investigator: Neusa Wandalsen, MD Less <<
NCT00489398 Allergic Conjunctivitis Phase 4 Withdrawn(Protocol changes) December 2008 -
NCT00584662 Chronic Rhinitis Not Applicable Terminated - United States, Florida ... More >> USF Tampa, Florida, United States, 33613 Less <<
NCT00769886 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Ophthalmic Research Consultants, Inc. North Andover, Massachusetts, United States, 01845 Less <<
NCT00770133 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Ophthalmic Research Consultants, Inc. North Andover, Massachusetts, United States, 01845 Less <<
NCT01390961 Allergic Conjunctivitis Phase 4 Unknown January 2012 United States, California ... More >> Milton M. Hom, OD, FAAO. Azusa, California, United States, 91702 Less <<
NCT01533220 Flu Cold ... More >> Allergic Disorder of Respiratory System Less << Phase 3 Unknown December 2013 Brazil ... More >> Instituto Paranaense de Otorrinolaringologia Curitiba, Parana, Brazil, 80620010 Less <<
NCT02433080 Endometrial Neoplasms Phase 2 Completed - United Kingdom ... More >> Barts Health NHS Trust London, Greater London, United Kingdom, E1 1BB University College London Hospital NHS Trust London, Greater London, United Kingdom, NW1 3AD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.05mL

0.81mL

0.41mL

20.26mL

4.05mL

2.03mL

40.53mL

8.11mL

4.05mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories